Codexis (CDXS) Competitors $2.25 -0.05 (-2.17%) Closing price 04/15/2025 04:00 PM EasternExtended Trading$2.20 -0.04 (-2.00%) As of 04/15/2025 04:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock CDXS vs. ZBIO, RIGL, VSTM, VNDA, EBS, XOMA, IRWD, SGMO, LXRX, and RGLSShould you be buying Codexis stock or one of its competitors? The main competitors of Codexis include Zenas Biopharma (ZBIO), Rigel Pharmaceuticals (RIGL), Verastem (VSTM), Vanda Pharmaceuticals (VNDA), Emergent BioSolutions (EBS), XOMA (XOMA), Ironwood Pharmaceuticals (IRWD), Sangamo Therapeutics (SGMO), Lexicon Pharmaceuticals (LXRX), and Regulus Therapeutics (RGLS). These companies are all part of the "biotechnology" industry. Codexis vs. Zenas Biopharma Rigel Pharmaceuticals Verastem Vanda Pharmaceuticals Emergent BioSolutions XOMA Ironwood Pharmaceuticals Sangamo Therapeutics Lexicon Pharmaceuticals Regulus Therapeutics Zenas Biopharma (NASDAQ:ZBIO) and Codexis (NASDAQ:CDXS) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, media sentiment, institutional ownership, risk, dividends, valuation, earnings and community ranking. Do institutionals & insiders hold more shares of ZBIO or CDXS? 78.5% of Codexis shares are owned by institutional investors. 2.1% of Codexis shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Which has better earnings & valuation, ZBIO or CDXS? Codexis has higher revenue and earnings than Zenas Biopharma. Codexis is trading at a lower price-to-earnings ratio than Zenas Biopharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioZenas Biopharma$5M72.90-$148.39M-$3.55-2.46Codexis$59.35M3.14-$76.24M-$0.90-2.50 Do analysts rate ZBIO or CDXS? Zenas Biopharma presently has a consensus target price of $40.00, suggesting a potential upside of 358.72%. Codexis has a consensus target price of $8.33, suggesting a potential upside of 270.37%. Given Zenas Biopharma's stronger consensus rating and higher probable upside, equities research analysts plainly believe Zenas Biopharma is more favorable than Codexis.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Zenas Biopharma 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Codexis 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67 Is ZBIO or CDXS more profitable? Zenas Biopharma has a net margin of 0.00% compared to Codexis' net margin of -96.35%. Zenas Biopharma's return on equity of 0.00% beat Codexis' return on equity.Company Net Margins Return on Equity Return on Assets Zenas BiopharmaN/A N/A N/A Codexis -96.35%-71.56%-38.00% Does the MarketBeat Community favor ZBIO or CDXS? Codexis received 349 more outperform votes than Zenas Biopharma when rated by MarketBeat users. However, 100.00% of users gave Zenas Biopharma an outperform vote while only 61.47% of users gave Codexis an outperform vote. CompanyUnderperformOutperformZenas BiopharmaOutperform Votes2100.00% Underperform VotesNo VotesCodexisOutperform Votes35161.47% Underperform Votes22038.53% Does the media prefer ZBIO or CDXS? In the previous week, Zenas Biopharma had 6 more articles in the media than Codexis. MarketBeat recorded 13 mentions for Zenas Biopharma and 7 mentions for Codexis. Codexis' average media sentiment score of 0.80 beat Zenas Biopharma's score of 0.01 indicating that Codexis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zenas Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 11 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Codexis 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryZenas Biopharma beats Codexis on 9 of the 16 factors compared between the two stocks. Remove Ads Get Codexis News Delivered to You Automatically Sign up to receive the latest news and ratings for CDXS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CDXS vs. The Competition Export to ExcelMetricCodexisIndustrial organic chemicals IndustryMedical SectorNASDAQ ExchangeMarket Cap$186.38M$2.08B$5.33B$7.57BDividend YieldN/A4.29%5.11%4.32%P/E Ratio-2.5915.6521.7317.81Price / Sales3.1412.05379.1994.60Price / CashN/A23.6238.1534.64Price / Book1.811.276.464.00Net Income-$76.24M-$13.51M$3.20B$247.23M7 Day Performance14.21%7.68%6.54%7.26%1 Month Performance-19.06%-12.97%-8.55%-6.26%1 Year Performance-16.36%-32.11%10.33%-0.18% Codexis Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CDXSCodexis3.1171 of 5 stars$2.25-2.2%$8.33+270.4%-16.4%$186.38M$59.35M-2.59250Gap DownZBIOZenas BiopharmaN/A$7.75+0.5%$40.00+416.1%N/A$323.94M$5M-2.18N/AHigh Trading VolumeRIGLRigel Pharmaceuticals2.7731 of 5 stars$17.04-1.2%$36.80+116.0%+48.2%$304.39M$179.28M121.72160News CoverageGap DownVSTMVerastem3.0557 of 5 stars$5.10-1.2%$13.88+172.1%-56.5%$262.58M$10M-1.6050VNDAVanda Pharmaceuticals4.1794 of 5 stars$4.19+1.2%$16.50+293.8%+7.6%$244.34M$198.77M-13.09290News CoveragePositive NewsEBSEmergent BioSolutions4.2309 of 5 stars$4.43-1.9%$14.33+223.3%+134.1%$240.88M$1.01B-1.082,420Positive NewsXOMAXOMA4.4425 of 5 stars$19.23-1.1%$72.00+274.4%-14.5%$230.36M$10.22M-5.5310News CoverageIRWDIronwood Pharmaceuticals4.6335 of 5 stars$1.27-5.2%$8.60+577.2%-90.7%$203.24M$351.41M-42.33220Analyst DowngradeShort Interest ↓News CoverageGap DownSGMOSangamo Therapeutics2.1975 of 5 stars$0.71+7.7%$5.17+630.9%+33.0%$158.85M$57.80M-0.94480High Trading VolumeLXRXLexicon Pharmaceuticals2.8275 of 5 stars$0.52+23.5%$3.67+608.7%-72.6%$127.40M$31.08M-0.69140Analyst ForecastGap DownHigh Trading VolumeRGLSRegulus Therapeutics2.4145 of 5 stars$1.60-5.0%$12.75+696.9%-29.9%$105.99MN/A-1.5030Short Interest ↑Gap Down Remove Ads Related Companies and Tools Related Companies ZBIO Alternatives RIGL Alternatives VSTM Alternatives VNDA Alternatives EBS Alternatives XOMA Alternatives IRWD Alternatives SGMO Alternatives LXRX Alternatives RGLS Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CDXS) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersTwo Unmistakable Patterns Return…The signs suggest we're entering one of those rare periods now. That's why Central Banks are buying gold at...Golden Portfolio | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredIs it CRAZY to still want reliable profits, despite this market?Larry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredTariffs. Volatility. Fear. Here’s the Plan.Wall Street's panicking over tariffs. Volatility's back with a vengeance. If you've been glued to the he...Investors Alley | SponsoredThis story is about to go viralThis Story Could Go Viral as Soon as May 31 Quietly, towns like Shreveport, Louisiana and Fort Worth, Texas...Stansberry Research | SponsoredHow War with China Could Start in 128 DaysThe clock is ticking. Those who aren't prepared could lose everything. I've identified 43 investments we...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Codexis, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Codexis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CDXS Stock Free CDXS Stock Alerts